CAV1 and diabetic kidney disease: Previous studies have shown that Cav-1 has antifibrotic properties by regulating cell proliferation, migration and adhesion, as well as inhibiting the TGF-β signaling pathway in diabetic kidney disease (DKD) (Gvaramia et al., 2013; Shihata et al., 2017; Van Krieken and Krepinsky, 2017).